Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Show more

117 Kendrick Street, Needham, MA, 02494, United States

https://www.candeltx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

358.9M

52 Wk Range

$4.25 - $7.25

Previous Close

$4.90

Open

$4.95

Volume

942,963

Day Range

$4.91 - $5.16

Enterprise Value

230.4M

Cash

119.7M

Avg Qtr Burn

-10.57M

Insider Ownership

15.80%

Institutional Own.

32.71%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CAN-2409 Details Intermediate/high-risk Prostate cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 + Valacyclovir w/ SoC Details Pancreatic ductal adenocarcinoma (PDAC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 + Valacyclovir w/ ICI treatments Details Lung cancer, Cancer, Solid tumor/s, III/IV Non-small cell lung carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 Details Cancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-3110 Details Solid tumor/s, Cancer, Glioma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 + Opdivo Details Cancer, Glioma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.